LIBRA trial: A Randomized trial to assess clinical utility of LINE-electronic patient reported outcomes for the management of adverse events in breast cancer patients treated with abemaciclib
Latest Information Update: 01 Mar 2022
At a glance
- Drugs Abemaciclib (Primary) ; Aromatase inhibitors; Fulvestrant; Leuprorelin
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions
- Acronyms LIBRA
- 28 Feb 2022 Status changed from not yet recruiting to recruiting.
- 15 Sep 2021 New trial record